文献速递糖尿病

阿卡波糖对冠心病合并糖耐量减低患者心血管和糖尿病结局的影响(ACE):一项随机、双盲、安慰剂对照试验

Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial.
PubMed 文献 · Lancet Diabetes Endocrinol · 2017-09-13

ACE试验在中国176家医院门诊纳入6522例冠心病合并糖耐量减低患者,随机接受阿卡波糖50mg每日三次或安慰剂,中位随访5.0年。阿卡波糖未减少主要不良心血管事件(HR 0.98,95%CI 0.86-1.11,p=0.73),但降低了糖尿病发生率(率比0.82,95%CI 0.71-0.94,p=0.005)。

要点

  • 阿卡波糖未降低冠心病合并糖耐量减低患者的主要心血管复合终点风险。
  • 阿卡波糖组糖尿病发生率低于安慰剂组(率比0.82,95%CI 0.71-0.94)。
  • 胃肠道疾病是导致停药或调整剂量的最常见不良事件。

核心结论

  • 在中国冠心病合并糖耐量减低患者中,阿卡波糖未降低主要不良心血管事件风险,但降低了糖尿病发生率。

研究设计与样本

  • ACE试验为随机、双盲、安慰剂对照的4期试验,从中国176家医院门诊招募患者。
  • 中国冠心病合并糖耐量减低患者按1:1随机分配接受口服阿卡波糖50mg每日三次或匹配安慰剂,均叠加于标准化心血管二级预防治疗。
  • 2009年3月20日至2015年10月23日共随机分配6522例患者纳入意向性治疗人群,阿卡波糖组3272例,安慰剂组3250例。

主要发现

  • 主要五联复合终点在阿卡波糖组3272例中发生470例(14%;3.33/100人年),安慰剂组3250例中发生479例(15%;3.41/100人年),风险比0.98(95%CI 0.86-1.11,p=0.73)。
  • 糖尿病在阿卡波糖组3272例中发生436例(13%;3.17/100人年),安慰剂组3250例中发生513例(16%;3.84/100人年),率比0.82(95%CI 0.71-0.94,p=0.005)。
  • 两组在次要三联复合终点、全因死亡、心血管死亡、致死或非致死性心肌梗死、致死或非致死性卒中、不稳定型心绞痛住院、心力衰竭住院或肾功能受损方面均未见显著差异。
  • 胃肠道疾病是导致停药或调整剂量的最常见不良事件,阿卡波糖组3263例中215例(7%) vs 安慰剂组3241例中150例(5%)(p=0.0007;安全性人群)。
  • 非心血管死亡(阿卡波糖组3272例中71例[2%] vs 安慰剂组3250例中56例[2%],p=0.19)和癌症死亡(阿卡波糖组3272例中10例[<1%] vs 安慰剂组3250例中12例[<1%],p=0.08)两组无差异。

关键数值与推荐

  • 主要终点为五点复合终点:心血管死亡、非致死性心肌梗死、非致死性卒中、不稳定型心绞痛住院和心力衰竭住院。
  • 次要终点包括三点复合终点(心血管死亡、非致死性心肌梗死、非致死性卒中)、全因死亡、心血管死亡、致死或非致死性心肌梗死、致死或非致死性卒中、不稳定型心绞痛住院、心力衰竭住院、糖尿病发生和肾功能受损发生。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The effect of the α-glucosidase inhibitor acarbose on cardiovascular outcomes in patients with coronary heart disease and impaired glucose tolerance is unknown. We aimed to assess whether acarbose could reduce the frequency of cardiovascular events in Chinese patients with established coronary heart disease and impaired glucose tolerance, and whether the incidence of type 2 diabetes could be reduced. METHODS: The Acarbose Cardiovascular Evaluation (ACE) trial was a randomised, double-blind, placebo-controlled, phase 4 trial, with patients recruited from 176 hospital outpatient clinics in China. Chinese patients with coronary heart disease and impaired glucose tolerance were randomly assigned (1:1), in blocks by site, by a centralised computer system to receive oral acarbose (50 mg three times a day) or matched placebo, which was added to standardised cardiovascular secondary prevention therapy. All study staff and patients were masked to treatment group allocation. The primary outcome was a five-point composite of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, hospital admission for unstable angina, and hospital admission for heart failure, analysed in the intention-to-treat population (all participants randomly assigned to treatment who provided written informed consent). The secondary outcomes were a three-point composite outcome (cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke), death from any cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, development of diabetes, and development of impaired renal function. The safety population comprised all patients who received at least one dose of study medication. This trial is registered with ClinicalTrials.gov, number NCT00829660, and the International Standard Randomised Controlled Trial Number registry, number ISRCTN91899513. FINDINGS: Between March 20, 2009, and Oct 23, 2015, 6522 patients were randomly assigned and included in the intention-to-treat population, 3272 assigned to acarbose and 3250 to placebo. Patients were followed up for a median of 5·0 years (IQR 3·4-6·0) in both groups. The primary five-point composite outcome occurred in 470 (14%; 3·33 per 100 person-years) of 3272 acarbose group participants and in 479 (15%; 3·41 per 100 person-years) of 3250 placebo group participants (hazard ratio 0·98; 95% CI 0·86-1·11, p=0·73). No significant differences were seen between treatment groups for the secondary three-point composite outcome, death from any cause, cardiovascular death, fatal or non-fatal myocardial infarction, fatal or non-fatal stroke, hospital admission for unstable angina, hospital admission for heart failure, or impaired renal function. Diabetes developed less frequently in the acarbose group (436 [13%] of 3272; 3·17 per 100 person-years) compared with the placebo group (513 [16%] of 3250; 3·84 per 100 person-years; rate ratio 0·82, 95% CI 0·71-0·94, p=0·005). Gastrointestinal disorders were the most common adverse event associated with drug discontinuation or dose changes (215 [7%] of 3263 patients in the acarbose group vs 150 [5%] of 3241 in the placebo group [p=0·0007]; safety population). Numbers of non-cardiovascular deaths (71 [2%] of 3272 vs 56 [2%] of 3250, p=0·19) and cancer deaths (ten [<1%] of 3272 vs 12 [<1%] of 3250, p=0·08) did not differ between groups. INTERPRETATION: In Chinese patients with coronary heart disease and impaired glucose tolerance, acarbose did not reduce the risk of major adverse cardiovascular events, but did reduce the incidence of diabetes. FUNDING: Bayer AG.

来源:Lancet Diabetes Endocrinol,查看原文。版权归原作者所有。

引用

  1. Holman RR, Coleman RL, Chan JCN, et al. Effects of acarbose on cardiovascular and diabetes outcomes in patients with coronary heart disease and impaired glucose tolerance (ACE): a randomised, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol. 2017. PMID: 28917545. doi:10.1016/S2213-8587(17)30309-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。